Fresenius Medical Care AG & Co. KGaA (FME.BE)
| Previous close | 38.74 |
| Open | 38.78 |
| Bid | 38.24 x 30000 |
| Ask | 38.79 x 50000 |
| Day's range | 38.42 - 38.78 |
| 52-week range | 31.04 - 49.52 |
| Volume | |
| Avg. volume | 172 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- Simply Wall St.
Fresenius Medical Care (ETR:FME) Will Be Hoping To Turn Its Returns On Capital Around
When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
- Reuters
Fresenius Medical sees up to 2% US dialysis growth by year-end
The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the pandemic on patients fades. Fresenius Medical Care is the world's largest kidney dialysis company, and the fallout from the pandemic - which led to an increase in deaths among patients - has weighed heavily on its shares. Fresenius Medical earlier this year said it anticipated a return to treatment volume growth in the U.S. over the course of 2024, as it slowly recovers from COVID-related deaths among its patients, many of whom suffer from a range of cardiovascular conditions.
